Elorac, Inc. Announces FDA Fast Track Designation for Novel Topical Treatment for Pruritus in Cutaneous T-cell Lymphoma (CTCL)

VERNON HILLS, Ill.--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s naloxone topical lotion for the relief of pruritus in patients with cutaneous T-cell lymphoma (CTCL). There are currently no approved therapeutic treatment options available to patients and their physicians for pruritus in CTCL. FDA describes Fast Track as “a process designed to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.” Fast Track designation offers the opportunity for earlier and more frequent interaction with FDA during a drug’s development, as well as a greater likelihood of receiving priority review from FDA.